< Back to the Blog

About the author

Amy Divaraniya
Dr. Aparna (Amy) Divaraniya is the Founder and CEO of Oova. She has over 10 years experience working in data science and a PhD in Biomedical Sciences. In 2017, Amy pivoted to women's healthcare after facing her own fertility struggles. Amy started Oova to give women control over their fertility by making high-quality hormone testing more accessible.

Sources

  1. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi:10.1136/bmj.k4810
  2. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428-432. doi:10.1016/S0140-6736(03)14066-4
  3. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845. doi:10.1161/CIRCULATIONAHA.106.642280
  4. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028
  5. Stute P, Wildt L, Neulen J. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016;19(4):316-328. doi:10.1080/13697137.2016.1187503
  6. Canonico M, Fournier A, Camus E, et al. Progestogens and venous thromboembolism among postmenopausal women: an updated meta-analysis. J Intern Med. 2010;268(6):571-582.
  7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
  8. Hodis HN, Mack WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: it is about time and timing. Cancer J. 2022;28(3):208-223.
  9. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202-216. doi:10.1097/01.AOG.0000441353.20693.78
  10. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168.

About the Oova Blog:
Our content is developed with a commitment to high editorial standards and reliability. We prioritize referencing reputable sources and sharing where our insights come from. The Oova Blog is intended for informational purposes only and is never a substitute for professional medical advice. Always consult a healthcare provider before making any health decisions.